Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | OXTR | P30559 | 3/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27961410 | 0.79 | AR (0.37) | ARKCNQ3KCNQ2CHEK1CTSA | |
| SCHEMBL21459806 | 0.79 | AR (0.37) | ARKCNQ3KCNQ2CHEK1CTSA | |
| SCHEMBL27582956 | 0.79 | PAX8 (0.43) | AROXTRBRAFGPBAR1AOC3 | |
| SCHEMBL129142 | 0.77 | ALDH1A1 (0.42) | ARCHEK1PANK3EGLN2 | |
| SCHEMBL1081803 | 0.77 | NPSR1 (0.41) | ARKCNQ3KCNQ2CHEK1CTSA | |
| SCHEMBL27663663 | 0.75 | GABRP (0.48) | OXTRHDAC6 | |
| SCHEMBL20576848 | 0.75 | OXTR (0.41) | OXTR | |
| SCHEMBL152511 | 0.74 | CHEK1 (0.42) | CHEK1OPRM1OPRL1EGLN2 | |
| SCHEMBL175286 | 0.73 | EGLN2 (0.36) | ARKCNQ3KCNQ2CHEK1OPRM1 | |
| SCHEMBL2767198 | 0.72 | KCNH2 (0.37) | OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7125883-B1 | Integrin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2006-10-24 | — | — | US | disclosed |
| US-7105508-B1 | Integrin receptors antagonists | ABBOTT GMBH & CO. KG (DE) | 2006-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | AR 1895/4885OXTR 917/4885KCNQ3 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.